## Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075

January 11, 2024

## **VIA EDGAR**

Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549

> Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443

To the addressees set forth above:

Reference is made to the letter from Evoke Pharma, Inc. (the "Company"), filed as correspondence via EDGAR on January 5, 2023, in which the Company requested that the effective date of the Registration Statement on Form S-1 referred to above (the "Registration Statement") be accelerated so that it would become effective at 4:00 P.M. Eastern Time on January 9, 2023, or as soon as practicable thereafter (the "Effective Time"), pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended.

The Company no longer requests that such Registration Statement be declared effective at the Effective Time, and the Company hereby withdraws its request for the acceleration of the effective date until providing further notice.

If you have any questions regarding the foregoing, please do not hesitate to contact Anthony Gostanian of Latham & Watkins LLP, counsel to the Company, at (858) 523-3969.

Very truly yours,

EVOKE PHARMA, INC.

By: /s/ David A. Gonyer
David A. Gonyer

Chief Executive Officer

 $|US\text{-}DOCS\backslash 147668126.2||$ 

cc: Matthew J. D'Onofrio, Evoke Pharma, Inc.
Matthew T. Bush, Latham & Watkins LLP
Anthony Gostanian, Latham & Watkins LLP
Richard A. Friedman, Sheppard, Mullin, Richter & Hampton LLP

|US-DOCS\147668126.2||